Sort   by:  
 Page size 
UnknownSARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Not available
S-EPMC8723827 | biostudies-literature
UnknownPara-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.
Not available
S-EPMC10746705 | biostudies-literature
UnknownImplementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study.
Not available
S-EPMC8940185 | biostudies-literature
UnknownThe P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.
Not available
S-EPMC10009825 | biostudies-literature
UnknownDelayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19.
Not available
S-EPMC11272059 | biostudies-literature
UnknownThe impact of viral mutations on recognition by SARS-CoV-2 specific T cells.
Not available
S-EPMC8552693 | biostudies-literature
UnknownSARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.
Not available
S-EPMC9762734 | biostudies-literature
UnknownEffects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.
Not available
S-EPMC11873788 | biostudies-literature
Sort   by:  
 Page size